02:33 , Jul 13, 2019 |  BioCentury  |  Finance

How crossover, insider support and big money correlated with performance across 1H19 IPOs

The performance of 1H19 IPOs point toward a continuation of a dual-class system where biotechs backed by deep-pocketed VCs and crossover investors can tap the public market at will and generate stronger after-market performance than...
18:54 , Jun 19, 2019 |  BC Extra  |  Financial News

June 19 Financial Quick Takes: Stoke rises after IPO; plus Polaris, Woodford, follow-ons

Stoke catches fire after pricing upsized IPO  Genetic diseases company Stoke Therapeutics Inc. (NASDAQ:STOK) gained $7.57 (42%) to $25.57 in its first day of trading Wednesday after raising $142 million in its IPO. The company...
00:43 , Jun 18, 2019 |  BC Extra  |  Clinical News

June 17 Clinical Quick Takes: VBI's HBV vaccine misses secondary endpoint, plus ArQule, Verastem and more

VBI falls with HBV vaccine miss on secondary endpoint  VBI Vaccines Inc. (NASDAQ:VBIV) sank $1.24 (66%) to $0.65 Monday after reporting that two doses of Sci-B-Vac failed to show non-inferior seroprotection at day 168 vs....
13:54 , Apr 10, 2019 |  BC Innovations  |  Distillery Therapeutics

Diazooxohexanoate-based prodrug of a GLS inhibitor for lymphoma

DISEASE CATEGORY: Cancer INDICATION: Lymphoma Cell culture studies identified a diazooxohexanoate-based prodrug of a GLS inhibitor that could help treat lymphoma. Chemical synthesis and screening of ester prodrugs of the GLS inhibitor 6-diazo-5-oxo-L-norleucine (DON) in...
18:42 , Mar 8, 2019 |  BC Extra  |  Company News

TNBC gets its first targeted agent with Tecentriq approval

The approval of Roche's Tecentriq atezolizumab to treat metastatic triple-negative breast cancer gives almost half of these patients and physicians' their first agent to treat a molecularly defined subgroup of patients with this fast-progressing cancer....
20:49 , Dec 19, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Neuroendocrine tumors Cell culture and mouse studies suggest inhibiting arginine-mediated signaling of the ARG2-SLC7A1 axis could help treat neuroblastoma. In a human neuroblastoma cell line, an shRNA against ARG2 decreased proliferation compared with a...
22:55 , Nov 15, 2018 |  BC Innovations  |  Product R&D

Tempest takes PPAR alpha into cancer

Tempest Therapeutics Inc.’s first data from its preclinical PPARα program gave it the support it was looking for to repurpose the cardiovascular target for cancer. Tapping into the emerging field of cancer immuno-metabolism, Tempest is...
00:33 , Sep 28, 2018 |  BC Innovations  |  Targets & Mechanisms

Cell metabolism’s migration

As cancer metabolism undergoes a renaissance in the clinic, with compounds targeting growth factor and nutrient sensing pathways, basic research on metabolic processes in all cells is shining light on pathways that could yield new...
15:18 , Sep 20, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Brain cancer Cell culture and mouse studies suggest inhibiting GLS could enhance the efficacy of radiation or reactive oxygen species (ROS)-inducing drugs in IDH1-mutant glioma. In a human glioma cell line expressing mutant IDH1,...
17:39 , Jun 1, 2018 |  BC Week In Review  |  Clinical News

Calithera reports Phase I data for CB-839 combo in solid tumors

Calithera Biosciences Inc. (NASDAQ:CALA) reported data from 16 evaluable patients with advanced solid tumors in the Phase I portion of a Phase I/II trial showing that twice-daily 400-800 mg doses of oral CB-839 plus Xeloda...